ÂÜÀòÂÒÂ×

Ash Alizadeh (M.D./Ph.D.) is a co-founder of Foresight Diagnostics and an Associate Professor of Medicine (Oncology) at Stanford University where he leads the Cancer Genomics program at the Stanford Cancer Institute. Dr. Alizadeh has a significant history of research and accomplishments in cancer genomics, beginning with the original development of microarray gene expression profiling for cancer classification starting with lymphomas, and advancing to multiple tumor types. In close collaboration with Dr. Diehn’s group, his research group at Stanford University has a long history of developing cancer genomic techniques, including for ultra-sensitive and non-invasive detection of tumor-derived cell-free DNA. Clinically, he is a practicing medical oncologist specializing in the care of patients with lymphoma, including diffuse large B-cell lymphomas (DLBCL). His clinical research is focused on diagnostic, prognostic, and predictive biomarkers and translating discoveries from the laboratory to the clinic using cutting tools in data science.